Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Keywords

Clinical Trial ×

Diabetes Mellitus ×

Show more Keywords

Table of contents

Select data models

Selected data models

You must log in to select data models for download or further analysis.

491 Search results.

Eligibility NCT00322621 Diabetic Neuropathies - Eligibility

- 8/11/14 - 1 form, 2 itemgroups, 9 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00322621

LASER ADMINISTRATION FELLOW EYE (UNSCHEDULED) CRFs Roche FVF4170G Macular Edema NCT00473382

- 6/28/17 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Patient administration,LASER ADMINISTRATION STUDY EYE

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

CONCURRENT OCULAR PROCEDURES (DAY 0 - MONTH 12) CRFs Roche FVF4170G Macular Edema NCT00473382

- 6/11/17 - 1 form, 3 itemgroups, 12 items, 1 language

Itemgroups: Patient administration,CONCURRENT OCULAR PROCEDURES (DAY 0 - MONTH 12),Procedure

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

SUBJECT ELIGIBILITY (SCREENING) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 6/8/17 - 1 form, 3 itemgroups, 9 items, 1 language

Itemgroups: Patient administration,SUBJECT ELIGIBILITY,Eligibility Criteria Not Met

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Visit 3 (Washout) Diabetes Mellitus-ASP1941-1941-CL-0004 NCT01071850

- 2/19/22 - 1 form, 4 itemgroups, 14 items, 1 language

Itemgroups: Date of Visit,Orthostatic Vital Signs,12 Lead ECG,Weight

A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes MellitusTEST Study Visit 3

Visit 10 Diabetes Mellitus-ASP1941-1941-CL-0004 NCT01071850

- 2/16/22 - 1 form, 4 itemgroups, 13 items, 1 language

Itemgroups: Date of Visit,Orthostatic Vital Signs,Weight,Waist and Hip Circumference

A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes MellitusTEST Study

Eligibility Diabetes NCT01028404

- 9/27/21 - 1 form, 2 itemgroups, 16 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01028404

Eligibility Diabetes Mellitus NCT01796834

- 9/27/21 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Managing Diabetes Mindfully Study; ODM derived from: https://clinicaltrials.gov/show/NCT01796834

Eligibility Diabetes Mellitus NCT02310555

- 9/27/21 - 1 form, 2 itemgroups, 14 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Surgical Techniques in Diabetes Mellitus-II and Obesity. Metabolic Surgery Study (MSS); ODM derived from: https://clinicaltrials.gov/show/NCT02310555

Eligibility Obstructive Sleep Apnea and Diabetes Mellitus NCT01136785

- 9/27/21 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Effects of Continuous Positive Airway Pressure (CPAP)Treatment on Glucose Control; ODM derived from: https://clinicaltrials.gov/show/NCT01136785

SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36) CRFs Roche FVF4170G Macular Edema NCT00473382

- 9/20/21 - 1 form, 7 itemgroups, 40 items, 1 language

Itemgroups: Patient administration,SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36),Adverse Event,Serious AE,Relevant Diagnostic Tests Performed,Tests,Additional Case Details:

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36) CRFs Roche FVF4168G Macular Edema NCT00473330

- 9/20/21 - 1 form, 7 itemgroups, 40 items, 1 language

Itemgroups: Patient administration,SERIOUS / NON-SERIOUS EXPEDITED ADVERSE EVENT REPORTING (DAY 0 - MONTH 36),Adverse Event,Serious AE,Relevant Diagnostic Tests Performed,Tests,Additional Case Details:

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.